Q&A With Chris Ecles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A With Chris Ecles
PharmTech speaks to Chris Eccles, managing director of ChargePoint Technology.

Pharmaceutical Technology
Volume 37, Issue 2



PharmTech: How has the increasing focus on biopharmaceuticals affected your business?

Eccles: As a company with a new sterile-product range designed to meet a very specific niche within traditional pharmaceutical processing, adapting to meet the developing requirements set by bioprocesses has been interesting. While this has been challenging, it has also presented opportunities and a new revenue stream for us. We have developed new products suited to specific bioprocessing applications as well as adapting some of our existing range of powder transfer valves. We have been able to offer solutions to the industry that allow manufacturers to process in a way that they previously couldn't. A fundamental element to this product development program has been knowledge. The learning curve has been steep in order to keep up with the pace of the industry and we have had to work closer than ever with customers to understand their needs. This shift in focus has also involved ensuring that we have product specialists for biopharmaceuticals, and their knowledge is spread though our teams.

PharmTech: Do you see a new industry trend emerging?

Eccles: We continue to see an increase in active ingredient toxicity levels that requires increasingly more stringent controls during production.

More and more of our customers' manufacturing techniques have a sterile requirement. In some cases, the sterile products being processed could also present some risk in terms of toxicity, which presents some unique challenges.

PharmTech: How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Eccles: From an equipment supplier perspective, we aim to stay in touch with our customers' needs and the requirements set by the regulators. We must increase the awareness of the solutions we have available to our customers that enable them to meet their regulatory targets.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here